ded increasingly in areas remote from the tropics. 89 The disease, which is characterised by painful ulcerative lesions of the genitalia and is often associated with painful regional lymphadenopathy, may easily be misdiagnosed as primary syphilis, lymphogranuloma venereum (LGV), or genital herpes. Until recently sulphonamides and tetracyclines were accepted as the treatment of choice for the disease.'`Cases refractory to treatment with these antimicrobial agents have, however, been recorded in both the Far East and Africa." 12 The availability of a solid agar medium devised by Hammond et Typical colonies of H ducreyi that could be pushed intact across the agar surface were identified according to the criteria of Kilian.'6 Swabs for isolating C trachomatis and HSV were inoculated into transport media and kept at 4°C for up to 24 hours. They were either processed within that period or frozen at -70°C. We attempted to isolate C trachomatis using cycloheximide treated McCoy cells,'7 and HSV using human foreskin fibroblasts.
Patients were excluded from the studies ifthey failed to give informed consent or had received any antimicrobial chemotherapy within the previous seven days or if dark field examination of their ulcer exudate proved positive for syphilis. Patients were subsequently excluded if C trachomatis or HSV were recovered from their lesions or if H ducreyi was not isolated. Patients with positive or presumptive serological evidence of syphilis or LGV (chlamydial microimmunofluorescence titres _ 1/256) were not excluded. Patients took single dose treatment under direct supervision. They were asked to refrain from sexual contact and to return for two follow up examinations (on days 7-10 and 14-21). Cultures for H ducreyi were repeated if the target ulcer had not reepithelialised, if the lymph nodes had become fluctuant, or if an inguinal ulcer had formed or persisted.
Results

ERYTHROMYCIN
Erythromycin has emerged as one of the drugs of choice for treating chancroid on the basis of both in vitro and in vivo data.'4 8 The dosage and duration of treatment with this antibiotic, however, have remained in question. '8 During a dose finding (unpublished) study three regimens involving six patients receiving a single dose of 1500 mg erythromycin, five patients receiving 500 mg three times a day for three days, and seven patients receiving 500 mg four times a day for four days gave unacceptable results. The clinical failure rate was five out of 12 and the microbiological failure rate was two out of 12 (six patients failed to return for follow up visits). The clinical responses of patients who were treated for three or four days were, however, better than those ofpatients given single dose treatment; only one out of four who were evaluable responded clinically.
Of 25 patients in that study who received erythromycin stearate 500 mg three times a day for five days and returned for follow up, 14 had epithelialised lesions and the ulcers of the others had decreased in size. In one case, however, H ducreyi was isolated again from the lesion. On day 14 three of the 25 patients defaulted, including the patient with the second positive culture. In the other 22 patients, epithelialisation was either complete (in 20 patients) or almost complete (in one patient). The ulcer in the remaining patient persisted, and H ducreyi was isolated again from the lesion. Overall, two treatment failures (8%) were recorded. Thus, although single dose treatment with erythromycin proved to be unsatisfactory, treatment at a dosage of 500 mg three times a day for five days should be adequate.
SULPHONAMIDE AND TRIMETHOPRIM PREPARATIONS
Sulphonamide and trimethoprim combinations have also been widely used to treat chancroid. Sulphamethoxazole and trimethoprim at a dosage of 800 and 160 mg twice a day for 10 days has been advocated as a suitable treatment regimen, and other sulphonamide and trimethoprim combinations have been evaluated in Kenya.'920 Despite encouraging results with sulphametrole and trimethoprim (3200 and 640 mg) as a single oral dose, higher failure rates have been recorded subsequently by the same workers, possibly as a result of the emergence of resistance to trimethoprim. Resistance to trimethoprim has also been recorded in Thailand." In southern Africa, isolates remain susceptible to trimethoprim, and sulphamethoxazole and trimethoprim (800 and 160 mg) given twice a day for 10 days continues to be adequate 
RESPONSE OF ULCERS AND LYMPHADENOPATHY TO TREATMENT
Initial responses (usually within 72 hours) to successful treatment of chancroid were a decrease in ulcer pain, the disappearance of the purulent base of ulcers, the onset of epithelialisation, and failure to isolate H ducreyi again. The rate of healing does not appear to depend solely on the antimicrobial agent or the duration of treatment, but was rather a function of the size and site of lesions, especially when they were in a subpreputial location. In contrast to the responses of ulcers, the patterns associated with lymphadenopathy are variable. In a few (about 10%) cases the regional lymph nodes may enlarge and become fluctuant despite the initiation of "successful" treatment. Repeated aspiration ofthese bubos may be required to prevent inguinal or femoral ulcers. Progression to In conclusion, future prospects for treating laboratory proved cases of chancroid are encouraging, with several short or single dose treatments becoming available. Provision ofthese treatments will depend on the recognition of chancroid as a public health problem, the susceptibilities of local Hducreyi isolates to antimicrobials, the availability of diagnostic facilities, and, inevitably, financial considerations.
